Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific share transaction.
| Transaction Detail | Value |
|---|---|
| Instrument | Ordinary Shares of 31 pence each (ISIN: GB00BN7SWP63) |
| Transaction Type | Purchase |
| Volume | 3,334 shares |
| Price per Share | £22.1926 |
| Transaction Date | February 20, 2026 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records an initial notification of a share purchase by Wendy Becker, an Independent Non-Executive Director.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a standard compliance report for insider trading activity.
Investor Verification Checklist
- Verify the total number of shares held by Wendy Becker following this transaction to assess total insider exposure.
- Confirm the transaction price of £22.1926 against the market closing price on February 20, 2026.
- Review the company's latest Form 20-F for comprehensive financial results, as this 6-K does not contain them.